Non-antibiotic CMTX-101 reduces lung bacteria in cystic fibrosis:...

Non-antibiotic CMTX-101 reduces lung bacteria in cystic fibrosis:...

Adding the experimental treatment CMTX-101 to standard antibiotics reduced the number of Pseudomonas aeruginosa — a type of bacteria often involved in serious infections — in the lungs of people with cystic fibrosis (CF), while also being safe and well tolerated. These are interim findings from 21 patients in a Phase 1b/2a clinical study (NCT06159725) that’s testing how safe CMTX-101 is compared with a placebo and how well it works as a single i…